Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 4/20 | 0.47 |
| ▸ | ANPEP | P15144 | 2/20 | 0.47 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.47 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.47 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 3/20 | 0.45 |
| ▸ | ACE | P12821 | 3/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | FPR1 | P21462 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8159887 | 1.00 | LAP3 (0.47) | LAP3ANPEPRNPEPDNPEPSPPL2A | |
| Hydrochloric Acid SCHEMBL5871977 | 0.99 | LAP3 (0.46) | LAP3ANPEPRNPEPDNPEPSPPL2A | |
| Hydrochloric Acid SCHEMBL7322995 | 0.99 | LAP3 (0.46) | LAP3ANPEPRNPEPDNPEPSPPL2A | |
| SCHEMBL5872214 | 0.91 | LAP3 (0.48) | LAP3ANPEPRNPEPDNPEPSPPL2A | |
| SCHEMBL6225204 | 0.91 | LAP3 (0.48) | LAP3ANPEPRNPEPDNPEPSPPL2A | |
| SCHEMBL3614651 | 0.83 | SPPL2A (0.52) | LAP3ANPEPRNPEPDNPEPSPPL2A | |
| SCHEMBL5405883 | 0.83 | MME (0.43) | MMEACEPSEN1PSEN2APH1B | |
| SCHEMBL5872287 | 0.83 | PSEN1 (0.44) | MMEACEPSEN1PSEN2APH1B | |
| SCHEMBL8762274 | 0.83 | MME (0.43) | MMEACEPSEN1PSEN2APH1B | |
| SCHEMBL5872022 | 0.83 | MME (0.43) | MMEACEPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226932-B2 | Self-emulsifying drug delivery system | G.D. SEARLE LLC (US) | 2007-06-05 | — | — | US | disclosed |
| US-20060270855-A1 | Methods of preparing retroviral proteases inhibitor intermediates | G.D. SEARLE & CO. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7060851-B2 | Method of preparing retroviral protease inhibitor intermediates | G.D. SEARLE & CO. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20050131075-A1 | Method of preparing retroviral protease inhibitor intermediates | G.D. SEARLE & CO. (US) | 2005-06-16 | — | — | US | disclosed |
| US-6849760-B2 | Method of preparing retroviral protease inhibitor intermediates | G. D. SEARLE & CO. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040048934-A1 | Self-emulsifying drug delivery system | G.D. SEARLE & CO. | 2004-03-11 | — | — | US | disclosed |
| EP-0970066-B1 | Preparation of aminoepoxides from aminoaldehydes and an in situ formed halomethyl organometallic reagent | SEARLE & CO (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030171612-A1 | Method of preparing retroviral protease inhibitor intermediates | G.D. SEARLE & CO. | 2003-09-11 | — | — | US | disclosed |
| US-6515162-B2 | Precipitating or crystallizing a salt from solution; suitable as intermediates for large scale production of enzyme inhibitors, e.g. hydroxyethylamine, hydroxyethylurea and hydroxyethylsulfonamide | G.D. SEARLE & CO. | 2003-02-04 | — | — | US | disclosed |
| EP-0855388-B1 | Method for making intermediates useful in synthesis of retroviral protease inhibitors | SEARLE & CO (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-1999059994-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1999-11-25 | — | — | WO | disclosed |
| EP-0855388-A2 | Method for making intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1998-07-29 | — | — | EP | disclosed |
| WO-1998029401-A1 | AMINOEPOXIDES FROM AMINOALDEHYDES AND IN-SITU FORMED HALOMETHYL ORGANOMETALLIC REAGENT | G.D. SEARLE & CO. (US) | 1998-07-09 | — | — | WO | disclosed |
| EP-0804410-A1 | METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5648511-A | Method for making intermediates useful in the synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1997-07-15 | — | — | US | disclosed |
| EP-0769936-A1 | SELF-EMULSIFYING DRUG DELIVERY SYSTEM | G.D. SEARLE & CO. (US) | 1997-05-02 | — | — | EP | disclosed |
| EP-0730570-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-11 | — | — | EP | disclosed |
| WO-1996022275-A1 | METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES | G.D. SEARLE & CO. (US) | 1996-07-25 | — | — | WO | disclosed |
| WO-1996003113-A1 | SELF-EMULSIFYING DRUG DELIVERY SYSTEM | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
| WO-1995014653-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270855-A1 | Methods of preparing retroviral proteases inhibitor intermediates | ACE, REN, MME | LAP3 148/4885ANPEP 9/4885RNPEP 4/4885 |
| US-20030171612-A1 | Method of preparing retroviral protease inhibitor intermediates | ACE, REN, MME | LAP3 193/4885ANPEP 9/4885RNPEP 5/4885 |
| US-20040048934-A1 | Self-emulsifying drug delivery system | LIPA, CEL, LSS | LAP3 3079/4885ANPEP 3293/4885RNPEP 2322/4885 |
| US-20050131075-A1 | Method of preparing retroviral protease inhibitor intermediates | ACE, REN, MME | LAP3 170/4885ANPEP 10/4885RNPEP 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.